Perjeta
Payments companies reported to CMS as associated with Perjeta. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Perjeta, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Perjeta
These are the largest totals companies reported as associated with Perjeta. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Sara Tolaney | Boston, MA | Hematology & Oncology | $29,744.09 |
| Chau Dang | New York, NY | Hematology & Oncology | $23,597.22 |
| Sandra Swain | Bethesda, MD | Hematology & Oncology | $17,610.81 |
| Maria Theodoulou | Albany, NY | Medical Oncology | $15,578.85 |
| Joyce O'Shaughnessy | Dallas, TX | Medical Oncology | $15,137.87 |
| Andrew Seidman | New York, NY | Medical Oncology | $14,780.85 |
| Marcus Goncalves | New York, NY | Endocrinology, Diabetes & Metabolism | $12,654.00 |
| Martin Dietrich | Rockledge, FL | Hematology & Oncology | $12,359.68 |
| Shanu Modi | New York, NY | Medical Oncology | $9,485.49 |
| Erika Hamilton | Nashville, TN | Hematology & Oncology | $7,967.68 |
Prescribed Perjeta?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.